MRT-8102, a highly selective NEK7-directed molecular glue degrader (MGD) developed to treat inflammatory conditions linked to NLRP3, IL-1β, and IL-6 dysregulation, expands Monte Rosa’s clinical ...

BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ...

Monte Rosa Therapeutics announced its first-quarter 2025 financial results and business updates, highlighting significant progress in its molecular glue degrader therapeutics portfolio. The ...

Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 337.50% and 235.52%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the ...

BOSTON (AP) — Monte Rosa Therapeutics Inc. GLUE) on Thursday reported first-quarter profit of $46.9 million. The Boston-based company said it had net income of 57 cents per share.

Monte Rosa Therapeutics, Inc. VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune ...

Monte Rosa Therapeutics: Q1 Earnings Snapshot May 8, 2025 BOSTON (AP) — BOSTON (AP) — Monte Rosa Therapeutics Inc. (GLUE) on Thursday reported first-quarter profit of $46.9 million.

Monte Rosa also reported a net income of $13.4 million for the quarter, a notable improvement from the net loss of $33.3 million in the same period last year.

From what we can see, insiders were net buyers in Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it.

Monte Rosa Therapeutics' stock falls as MRT-2359 faces challenges in targeting CRPC. Click here to read an analysis of GLUE stock now.

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report)‘s stock had its “outperform” rating reaffirmed by investment analysts at Wedbush in a report released on Thursday, ...